Fernando Nobre

Fernando Nobre

Auto-generated profile, based on publicly available information

Fernando Nobre

Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
WBWeimar Kunz Sebba Barroso
Weimar Kunz Sebba Barroso
CRCibele Isaac Saad Rodrigues
Cibele Isaac Saad Rodrigues
LBLuiz Bortolotto
Luiz Bortolotto
MMMarco Antônio Mota-Gomes
Marco Antônio Mota-Gomes
ABAndréa Araujo Brandão
Andréa Araujo Brandão
WNWilson Nadruz
Wilson Nadruz
Sumário 1. Definição, Epidemiologia e Prevenção Primária 528 1.1 Definição de Hipertensão Arterial 528 […] Diretrizes Brasileiras de Hipertensão Arterial – 2020 Sumário 1. Definição, Epidemiologia e Prevenção Primária 528 1.1 Definição de Hipertensão Arterial 528 […] Diretrizes Brasileiras de Hipertensão Arterial – 2020

18 September 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Closed access
ABAndréa Araujo Brandão
Andréa Araujo Brandão
CRCibele Isaac Saad Rodrigues
Cibele Isaac Saad Rodrigues
LBLuiz Bortolotto
Luiz Bortolotto
AAAnderson da Costa Armstrong
Anderson da Costa Armstrong
RMRogério Andrade Mulinari
Rogério Andrade Mulinari
WNWilson Nadruz
Wilson Nadruz

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
AFAudes Diogenes de Magalhães Feitosa
Audes Diogenes de Magalhães Feitosa
WBWeimar Kunz Sebba Barroso
Weimar Kunz Sebba Barroso
DJDecio Mion Junior
Decio Mion Junior
FNFernando Nobre
Fernando Nobre
MMMarco Antonio Mota-Gomes
Marco Antonio Mota-Gomes
WNWilson Nadruz
Wilson Nadruz
Table of contents Updates and modifications to the Brazilian Guidelines for In-Office and Out-of-Office Blood Pressure Measurement 10 Part 1 – Blood pressure measurement 10 […] Brazilian Guidelines for In-office and Out-of-office Blood Pressure Measurement – 2023 Table of contents Updates and modifications to the Brazilian Guidelines for In-Office and Out-of-Office Blood Pressure Measurement 10 Part 1 – Blood pressure measurement 10 […] Brazilian Guidelines for In-office and Out-of-office Blood Pressure Measurement – 2023

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
AFAudes Diogenes de Magalhães Feitosa
Audes Diogenes de Magalhães Feitosa
WBWeimar Kunz Sebba Barroso
Weimar Kunz Sebba Barroso
DJDecio Mion Junior
Decio Mion Junior
FNFernando Nobre
Fernando Nobre
MMMarco Antonio Mota-Gomes
Marco Antonio Mota-Gomes
WNWilson Nadruz
Wilson Nadruz
Sumário Atualizações e Mudanças nas Diretrizes Brasileiras de Medidas da Pressão Arterial Dentro e Fora do Consultório 10 Parte 1 – Medidas da Pressão Arterial 10 […] Diretrizes Brasileiras de Medidas da Pressão Arterial Dentro e Fora do Consultório – 2023 Sumário Atualizações e Mudanças nas Diretrizes Brasileiras de Medidas da Pressão Arterial Dentro e Fora do Consultório 10 Parte 1 – Medidas da Pressão Arterial 10 […] Diretrizes Brasileiras de Medidas da Pressão Arterial Dentro e Fora do Consultório – 2023

5 March 2011 in Trials
Verified
Journal Article
Open access
PDF file
FFFlávio Danni Fuchs
Flávio Danni Fuchs
SFSandra Fuchs
Sandra Fuchs
LMLeila Beltrami Moreira
Leila Beltrami Moreira
MGMiguel Gus
Miguel Gus
ANAntônio C Nóbrega
Antônio C Nóbrega
OBOtávio Berwanger
Otávio Berwanger
Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage. This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil. Clinical Trials NCT00970931 .

1 October 2005 in Blood Pressure Monitoring
Verified
Journal Article
Closed access
FNFernando Nobre
Fernando Nobre
DMDécio Mion
Décio Mion
Ambulatory blood pressure monitoring (ABPM) provides relevant data about blood pressure over a 24-h period. The analysis of parameters to determine the blood pressure profile from these data is of great importance. To calculate areas under systolic and diastolic blood pressure curves (SBP-AUC/DBP-AUC) and compare with systolic and diastolic blood pressure load (SBPL/DBPL) and 24-h systolic and diastolic blood pressure (24-h SBP/24-h DBP) in order to determine which provides the best correlation with left ventricular mass index (LVMI). ABPM measurements (1143 individuals) were analyzed to obtain 24-h SBP/24-h DBP, SBPL/DBPL, and SBP-AUC/ DBP-AUC, using Spacelabs (90207) and CardioSistemas devices. Left ventricular mass was determined using an echocardiograph HP Sonos 5500 and LVMI was calculated. The correlations between all possible pairs within the group 24-h SBP/SBPL/SBP-AUC and 24-h DBP/DBPL/DBP-AUC were high and statistically significant. The correlations between 24-h SBP/24-h DBP and SBP-AUC/DBP-AUC with SBPL/DBPL close to 100%, were lower than those mentioned above. The correlations of the parameters obtained by ABPM with LVMI were also high and statistically significant, except for blood pressure load between 90 and 100%, and for 24-h SBP of 135 mmHg or less and SBPL higher than 50%. SBPL/DBPL and SBP-AUC/DBP-AUC can be used for the evaluation of ABPM data owing to the strong correlation with 24-h SBP/24-h DBP and with LVMI, except when SBPL is close to 100% or 24-h SBP is below 135 mmHg but SBPL is above 50%. SBP-AUC/DBP-AUC, however, are a better alternative because they do not have the limitations of blood pressure load or even of 24-h blood pressure present.